Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
BURLINGAME, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present initial clinical data from its Phase 1/1b clinical trial of CPI-006 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Corvus will present data on CPI-006 in an oral presentation and a poster session:
Abstract 2505: Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers. Presenter: Jason Luke, M.D., Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center Session Title: Oral Abstract Session: Developmental Immunotherapy and Tumor Immunobiology Date and Time: Sunday, June 2, 2019 from 9:24 am – 9:36 am CT Location: Hall D2 / McCormick Place, Chicago, Illinois A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a Poster 289a: single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers. Presenter: Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer Poster Session: Developmental Immunotherapy and Tumor Immunobiology Date and Time: Saturday, June 1, 2019 from 8:00 am – 11:00 am CT Location: Hall A / McCormick Place, Chicago, Illinois
ASCO Investor & Analyst ReceptionCorvus will host an investor and analyst reception on Sunday, June 2, 2019 at 6:00 pm CT, to discuss the data on CPI-006 presented at ASCO. The reception will feature Dr. Luke along with Richard A. Miller, M.D., president and chief executive officer of Corvus, and Mehrdad Mobasher, M.D., vice president and chief medical officer of Corvus. For information on attending the reception, please reach out to Zack Kubow at email@example.com. There will be live webcast of the reception, which may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for one year.
About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidate, ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, is currently being evaluated in a multicenter amended Phase 1b/2 clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of ciforadenant both as a single agent and in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. In May 2017, Corvus and Genentech expanded the collaboration and are now conducting a trial of ciforadenant and atezolizumab in patients with non-small cell lung cancer (NSCLC) who have failed prior therapies with anti-PD-(L)1 and platinum-based chemotherapy. Corvus is evaluating two additional product candidates: CPI-006, a humanized monoclonal antibody directed against CD73, in a multicenter Phase 1/1b clinical trial in patients with various solid tumors, and CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522 LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure +1 213-262-9390 firstname.lastname@example.org